



PeptideStacks.ca

COMMUNITY-REPORTED RESEARCH SUMMARY

IGF-1LR3

1 MG

Preparation examples, syringe conversion, community-reported patterns and important limitations.

PRODUCT SCOPE

Live PeptideStacks variants: 1 MG

Prepared 7 August 2026 | Sources reviewed 2026-08-07

Educational use only - not medical advice

IGF-1LR3 - preparation and dose math

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

1 MG vial - 2 mL example

Add 2 mL bacteriostatic water

Concentration: 0.5 mg/mL

Each U-100 unit = 5 mcg

1 MG vial - 1 mL example

Add 1 mL bacteriostatic water

Concentration: 1 mg/mL

Each U-100 unit = 10 mcg

Conversion table

Reported amount	1 MG setup	1 MG setup
10 mcg	2 units	1 units
20 mcg	4 units	2 units
50 mcg	10 units	5 units
100 mcg	20 units	10 units

CALCULATION CHECK

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

IGF-1LR3 - community-reported patterns

Anecdotal summary of the cited community discussions. These observations are descriptive, not a recommendation or evidence of safety or efficacy.

Recurring report	Frequency seen	Context in reports
10-20 mcg	Once daily	Lower-start reports
20-50 mcg	Once daily	Most recurring range
50-100 mcg	Daily in some reports	Higher experimental use

What recurred across reports

- Community discussions most often centered on muscle growth, recovery and nutrient-partitioning goals.
- The amount, frequency, route and cycle length varied substantially between reports.
- Reported outcomes were commonly confounded by diet, training, other products or existing treatment.

Important limitations

- IGF-1 activity can cause hypoglycemia and may promote unwanted tissue growth; unsupervised exposure is high risk.
- Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.

! Important Medical Disclaimer

EDUCATIONAL INFORMATION ONLY

This document summarizes calculation examples and community discussion about IGF-1LR3. It is not medical advice, a prescription, a diagnosis, a treatment plan, or a recommendation to use, inject, purchase, compound, or administer any product.

COMMUNITY REPORTS ARE NOT CLINICAL EVIDENCE

Online community posts are self-reported, uncontrolled, may be inaccurate, and cannot establish identity, purity, dosing accuracy, safety, efficacy, or causation. The ranges shown describe what was reported; they do not define an appropriate dose.

PROFESSIONAL DIRECTIONS PREVAIL

Use only under the direction of a licensed healthcare professional and qualified dispensing pharmacy. Follow the supplied concentration, diluent, storage, beyond-use date, injection technique, monitoring and individualized directions.

RECONSTITUTION AND INJECTION RISK

Incorrect concentration, syringe selection, unit conversion, handling, storage or sterile technique can cause unintended dosing, contamination, infection, abscess, tissue injury or allergic reaction.

WHEN TO SEEK URGENT CARE

Stop and seek urgent medical attention for trouble breathing, facial or throat swelling, fainting, chest pain, severe confusion, persistent vomiting, or signs of a serious injection-site infection.

SOURCE BASIS

PubMed literature search: IGF-1LR3 - <https://pubmed.ncbi.nlm.nih.gov/?term=IGF-1LR3> - retrieved 2026-08-07